Temozolomide promotes genomic and phenotypic changes in glioblastoma cells

BACKGROUND: Temozolomide (TMZ) is a first-line drug for the treatment of glioblastoma. Long-term TMZ-treated tumour cells acquire TMZ resistance by profound reprogramming of the transcriptome, proteome, kinome, metabolism, and demonstrate versatile and opposite changes in proliferation, invasion, in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell Int
Main Authors: Stepanenko, Aleksei A., Andreieva, Svitlana V., Korets, Kateryna V., Mykytenko, Dmytro O., Baklaushev, Vladimir P., Huleyuk, Nataliya L., Kovalova, Oksana A., Kotsarenko, Kateryna V., Chekhonin, Vladimir P., Vassetzky, Yegor S., Avdieiev, Stanislav S., Dmitrenko, Vladimir V.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Primary Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4858898/
https://ncbi.nlm.nih.gov/pubmed/27158244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-016-0311-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados